Takip et
Vineethkrishna Chandrasekar
Vineethkrishna Chandrasekar
DPhil Clinical Medicine Student, University of Oxford
ndm.ox.ac.uk üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer
A Kulkarni, V Chandrasekar, SK Natarajan, A Ramesh, P Pandey, ...
Nature biomedical engineering 2 (8), 589, 2018
1632018
Reporter nanoparticle that monitors its anticancer efficacy in real time
A Kulkarni, P Rao, S Natarajan, A Goldman, VS Sabbisetti, Y Khater, ...
Proceedings of the National Academy of Sciences 113 (15), E2104-E2113, 2016
752016
A microfluidic platform for drug screening in a 3D cancer microenvironment
HJ Pandya, K Dhingra, D Prabhakar, V Chandrasekar, SK Natarajan, ...
Biosensors and Bioelectronics 94, 632-642, 2017
642017
Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance
A Goldman, S Khiste, E Freinkman, A Dhawan, B Majumder, J Mondal, ...
Science signaling 12 (595), eaas8779, 2019
582019
Combining immune checkpoint inhibitors and kinase-inhibiting supramolecular therapeutics for enhanced anticancer efficacy
A Kulkarni, SK Natarajan, V Chandrasekar, PR Pandey, S Sengupta
ACS nano 10 (10), 9227-9242, 2016
442016
Algorithm for designing nanoscale supramolecular therapeutics with increased anticancer efficacy
A Kulkarni, P Pandey, P Rao, A Mahmoud, A Goldman, V Sabbisetti, ...
ACS nano 10 (9), 8154-8168, 2016
212016
AT1965, a novel B cell-activating immunotherapy, exerts potent anticancer activity
M Roy, V Krishna, A Sengupta, S Roy, A Kulkarni, S Sengupta
Cancer Research 78 (13 Supplement), 4712-4712, 2018
2018
Towards understanding the cellular uptake patterns of nano-particles among different immune cell lines
N Ismail, A Kulkarni, S Kumar, V Krishna, S Sengupta
Cancer Research 77 (13 Supplement), 4610-4610, 2017
2017
Abstract B52: 2-in-1 “sniper” nanomedicines rescue dendritic cells by two pronged inhibition of JAK2/STAT-3 and p38 MAPK pathways
SK Natarajan, V Chandhrasekar, N Ismail, S Swaminathan, S Sengupta, ...
Cancer Research 77 (2 Supplement), B52-B52, 2017
2017
Abstract LB-059: Supramolecular fusion nanotherapeutic mediated synergistic inhibition of PI3K and MEK pathways
V Chandrasekar, SK Natarajan, S Sengupta, A Kulkarni
Cancer Research 76 (14 Supplement), LB-059-LB-059, 2016
2016
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–10